Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From LifeNet Health
Global sales of orthobiologics products are expected to reach $2.8bn by 2024, a CAGR of 3.2%, led by the rising aging population and musculoskeletal disease.
Market Brief: Global Orthobiologics Market Will Reach $2.3Bn By 2023 With Highest Growth In Cartilage Replacement
The global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration is expected to reach $2.3bn by 2023, according to a new report by Informa's Meddevicetracker. This highly competitive market, which is led by Arthrex and other large and smaller players, continues to grow amid the rising prevalence of musculoskeletal soft tissue injuries and osteoarthritis. High prices of implants, the limited availability of donated tissue and limited reimbursement for synthetic scaffolds are limiting growth in this market.
Girls with elevated urinary concentrations of methyl paraben and propyl paraben biomarkers at age nine showed signs of entering puberty earlier than their peers, according to a UC Berkeley study focused on possible adverse impacts of personal-care product use. More news in brief.
Global sales of orthobiologics for musculoskeletal soft tissue replacement and regeneration are predicted to hit $1.4bn by 2021, driven largely by rising numbers of sports injuries requiring treatment, but also by a higher prevalence of osteoarthritis and a need for innovative treatments for musculoskeletal repair. This article offers an in-depth look at the orthobiologics market landscape for cartilage, meniscus and ligament/tendon replacement and regeneration, as well as insight from an orthopedic surgeon. It also analyzes key players in these markets and highlights emerging trends and the greatest barriers for wider adoption of products.
- Academic and Research Institutions
- Other Names / Subsidiaries
- AlloTiss Gemeinnützige Gewebebank GmbH
- Vivo Biosciences, Inc.
- Samsara Sciences, Inc.